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hrombosis and Inflammation?*
a˙l Aukrust, MD, PHD,†‡
an Kristian Dama˙s, MD, PHD,†
ils Olav Solum, PHD†
slo, Norway
latelet adhesion and aggregation at the site of plaque
upture is a crucial event in thrombus formation and the
evelopment of acute coronary syndrome (ACS). However,
ecent studies suggest that platelets also may trigger ACS
hrough other mechanisms such as the stimulation of an
nflammatory response. Thus, several studies suggest a role
or platelets as inflammatory cells (1,2). First, platelets
elease a wide range of inflammatory mediators from intra-
ellular stores, such as several chemokines. Second, platelets
ot only express and release inflammatory mediators but
ay upon activation also induce the expression of such
ubstances in other cells (e.g., monocytes/macrophages and
See page 2319
ranulocytes). Finally, platelets may themselves respond to
nflammatory mediators. In fact, platelets recently have been
ound to express several chemokine receptors that upon
timulation enhance platelet activation. Hence, during ac-
ivation platelets may not only promote thrombus formation
ut also seem to release and express inflammatory media-
ors, induce an inflammatory response within leukocytes and
ndothelial cells, and respond with activation to several of
he inflammatory mediators produced by these cells.
Recently, much attention has been focused on the role of
latelet-derived CD40 ligand (CD40L) in this inflamma-
ory loop between platelets and other cells (2,3). Platelet-
erived CD40 ligand, a transmembrane protein structurally
elated to tumor necrosis factor-alpha, originally was iden-
ified on CD4 T cells but has recently been found also on
ast cells, basophils, eosinophils, and activated platelets
2,3). Soluble CD40L (sCD40L) is found to be elevated in
oronary disease, particularly in patients with ACS (4), and
as been associated with increased cardiovascular risk in
pparently healthy women (5). Several lines of evidence
uggest that these findings not only represent epiphenom-
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Research Institute for Internal Medicine; and ‡Clinical Immunologyrnd Infectious Diseases, Rikshospitalet, Oslo, Norway.na but also may reflect important pathogenic processes in
hese patients. Both membrane-bound and sCD40L may
nteract with CD40—which is constitutively expressed on a
ide range of cells such as macrophages, endothelial cells,
ascular smooth muscle cells, and platelets—resulting in
arious inflammatory responses (2,3,6). Thus, the in vitro
timulation of CD40 signaling in atheroma-derived cells
esults in the production of cytokines, tissue factor, matrix
etalloproteinases (MMPs), and adhesion molecules
2,3,6). In vivo, an important role for the CD40L-CD40
nteraction in atherogenesis was demonstrated using mice
hat were deficient in CD40L and apolipoprotein E (apoE)
howing a dramatic decrease in plaque area in these mice
ompared with normal apoE-deficient animals (7). The
ossible plaque-stabilizing effect of CD40L neutralization
as further demonstrated in another study where the
dministration of anti-CD40L antibody to apoE-deficient
ice induced a stable plaque phenotype (8).
Recently, the list of biological activities of CD40L was
xtended from regulation of immune responses to induction
f platelet activation and thrombus formation. Thus, Andre´
t al. (9) showed that CD40L can stabilize arterial thrombi
y an intergrin-dependent mechanism. It is unclear whether
oth the transmembrane and the soluble forms of CD40L
re active in promoting platelet activation, but recombinant
CD40L alone was shown to enhance integrin-mediated
latelet aggregation at high shear rates, restoring normal
hrombosis in CD40L/ mice (9). These authors have
ore recently suggested that sCD40L is a ligand for
lycoprotein (GP) IIb/IIIa, inducing platelet stimulation as
videnced by the generation of platelet microparticles (10).
n the other hand, others have suggested that sCD40L
ay activate platelets through CD40 ligation, inducing
elease from both alpha- and dense-granule (11). Whatever
echanism, these studies suggest that CD40L may be
nvolved in thrombus formation and platelet activation,
eading to further increase in sCD40L release, representing
self-perpetuating pathogenic loop in this process.
It is estimated that 95% of the circulating sCD40L is
erived from platelets. Therapeutic strategies aiming to
lock the interaction between sCD40L and CD40 should
herefore focus on the possibility of blocking the release of
CD40L from these cells. It was originally suggested that
CD40L, upon platelet activation, was released from alpha-
ranule (4), but in contrast to the rapid release from these
ranules (within minutes), the release of sCD40L is much
lower, with a maximum between 45 and 100 min (12). The
revailing idea today is, therefore, that CD40L is surface-
xposed in a fast process and that sCD40L is then released
rom this membrane-bound CD40L as a degradation prod-
ct in a slow proteolytic process. However, at present
mbiguity exists regarding the exact mechanisms for
CD40L generation. In this issue of the Journal, Furman et
l. (13) extend our knowledge of the regulation of sCD40L
elease from platelets. First, they show that GP IIb/IIIa
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June 16, 2004:2326–8 Editorial Commentctivation is involved in the release of sCD40L, showing a
locking effect of GP IIb/IIIa antagonist, as also demon-
trated by others (14), and by showing that patients with
lanzmann thrombasthenia, an inherited deficiency of GP
Ib/IIIa on platelets, have a markedly decreased release of
CD40L upon platelet activation. Second, the authors also
how that although GP IIb/IIIa blocking or deficiency
educed sCD40L release, it did not affect the activation-
ependent translocation of CD40L to the platelet surface,
hich is in line with the idea that the up-regulation of the
embrane-bound CD40L and release of sCD40L in plate-
ets are regulated differently.
Glycoprotein IIb/IIIa antagonists block the binding of
oluble fibrinogen to the GP IIb/IIIa receptor on the
latelet surface, thereby inhibiting platelet aggregation. The
ffectiveness of intravenous GP IIb/IIIa antagonists in
reventing ischemic complications after percutaneous coro-
ary intervention has been well documented. Interestingly,
ome trials suggest that the clinical benefit extends well past
he time of short-term administration of GP IIb/IIIa
ntagonists (15). Herein, Furman et al. (13) show that GP
Ib/IIIa antagonists are able to inhibit the release of
CD40L from activated platelets, and others have previously
hown that these antagonists may reduce the platelet
D40L-mediated activation of endothelial cells (16). These
bservations may suggest that long-term benefit of these
ntagonists could be due not only to the inhibition of the
hort-term ischemic complications but also to the inhibition
f the autocrine function of sCD40L, interrupting the effect
f sCD40L on platelets, resulting in decreased thrombotic
nd inflammatory effects of sCD40L. Interestingly, others
ave shown that concentrations of GP IIb/IIIa antagonists
hat give less than robust inhibition of platelet aggregation
ctually potentate the release of sCD40L (14). Orally
vailable GP IIb/IIIa antagonists typically are administered
t suboptimal doses to prevent nuisance bleeding. It remains
o be determined whether these suboptimal doses cause the
ncreased generation of sCD40L, contributing to the ob-
erved trend of a negative benefit in clinical trials with these
rugs (17). Aspirin, inhibiting COX-1, and clopidogrel, a
ommonly used anti-platelet drug that inhibits the P2Y12
DP receptor, also block sCD40L release from platelets—
ut only in response to collagen and adenosine diphosphate
14,18). Whether this will also be reflected by a lessening of
he anti-thrombotic and anti-inflammatory effects of these
edications compared with GP IIb/IIIa antagonist remains
o be determined. The cleavage and release of sCD40L may
nvolve an intermediate step, such as activation of the
D40L protease, or modification of the substrate, CD40L
3,12). Precedent exists for the interaction of beta3-integrins
ith MMPs, the class of proteinases implicated in the
hedding of ligands in the tumor necrosis factor-alpha
uperfamily. The findings by Furman et al. (13) further
upport such a notion by demonstrating that the release of
CD40L from platelets is at least partly regulated by actin
olymerization and an MMP-inhibitor-sensitive pathway.uture studies will clarify whether these mechanisms rep-
esent suitable targets for blocking sCD40L release.
The anuclear platelet is being rediscovered as an intrigu-
ng link between thrombosis and inflammation, and
D40L-CD40 interaction seems to play an important role
n this process. This ligand has the unique property of
romoting both inflammatory and thrombotic responses;
ctivating endothelial cells, leukocytes, and platelets; and
perating in a self-perpetuating feedback loop. However,
everal questions remain to be resolved. Thus, although
everal studies have demonstrated thrombotic and inflam-
atory effects of recombinant trimeric sCD40L, the effects
f natural sCD40L have been questioned (15). Also, an
mportant question is whether the concentrations of
CD40L can become high enough to be biologically rele-
ant in the plaque even if this is not reflected in the
oncentration of sCD40L in the circulation (13). Moreover,
he mechanisms of sCD40L release in platelets are far from
lear and will have to be studied further. Furthermore, the
bility of anti-platelet drugs—and their optimal dosage—to
nhibit sCD40L release or sCD40L-CD40/sCD40L-GP
Ib/IIIa interaction on platelets will have to be clarified.
lso, some thromboembolic complications were reported in
oth CD40L/ mice and humans receiving antibodies to
D40L, reflecting the possibility that inhibition of platelet
D40L might render platelet plugs unstable (12,19). On
he other hand, the inhibition of CD40L effects could help
o prevent thrombus formation, and the exact role of
CD40L in thrombus formation and stabilization and the
linical consequences of anti-CD40L therapy is, at present,
ot clear. All these issues will have to be further clarified in
orthcoming studies that provide greater insight into
latelet-dependent mechanisms involved in the regulation
f vascular and inflammatory disease, possibly leading to
ew treatment modalities in these disorders.
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